Vernalis and Servier reach first oncology milestone
This article was originally published in Scrip
Vernalisand the privately held French pharmaceutical company Servierhave achieved the first milestone in their three-year oncology drug discovery collaboration that was signed in May last year. The milestone, which will see Servier pay Vernalis $500,000, marks the solving of the novel crystal structure of an undisclosed oncology target. As part of the joint research programme Servier funds Vernalis's scientists and applies Vernalis's structure-based discovery capabilities to two oncology targets involved in protein-protein interactions.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.